Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and... Read More
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and... Read More
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asci... Read More
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib wit... Read More
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy... Read More
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitax... Read More
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/1b Study of IAM1363 in Participants with Advanced Cancers Harboring HER2 Alterations'. ... Read More
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with or ... Read More
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'An Interventional, Open-Label, Phase 2 Study to Investigate the Safety and Efficacy of PF-0863440... Read More
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the e... Read More